Vivos Therapeutics (VVOS) Shares Outstanding (2019 - 2026)

Vivos Therapeutics (VVOS) has reported Shares Outstanding (Entity) for 8 consecutive years, with $14.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Shares Outstanding (Entity) rose 98.39% year-over-year to $14.5 million in Q2 2026; TTM through Jun 2026 was $14.5 million, a 98.39% increase from a year earlier, with the FY2025 full-year figure at $9.3 million, up 57.68% from the prior year.
• Shares Outstanding (Entity) was $14.5 million for Q2 2026 at Vivos Therapeutics, up from $13.5 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $14.5 million in Q2 2026 and troughed at $920485.0 in Q1 2022.
• A 5-year average of $5.1 million and a median of $3.1 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Across the five-year window, Shares Outstanding (Entity) changed 0.0% in 2022 and jumped 452.54% in 2024, its largest moves.
• Over 5 years, Shares Outstanding (Entity) stood at $920485.0 in 2022, then surged by 32.47% to $1.2 million in 2023, then jumped by 382.99% to $5.9 million in 2024, then surged by 57.68% to $9.3 million in 2025, then surged by 56.48% to $14.5 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $14.5 million (Q2 2026), $13.5 million (Q1 2026), and $9.3 million (Q4 2025), per Business Quant data.